COVID-19: guidance for those leading a nomadic way of life

 Click here for government guidance

NHS operational planning and contracting guidance 2020/21

This guidance covers system planning, full operational plan requirements, details of workforce transformation requirements, the financial settlement and the process and timescales around the submission of plans that the NHS must plan to do during 2020/21. Click here for NHS guidance

New NICE guideline [NG99] Brain tumours (primary) and brain metastases in adults

New NICE guideline [NG99] Brain tumours (primary) and brain metastases in adults


Published date: July 2018    


This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.


For full guidance
https://www.nice.org.uk/guidance/ng99           

New NICE guideline [NG98] Hearing loss in adults: assessment and management

New NICE guideline [NG98] Hearing loss in adults: assessment and management


Published date: June 2018                


This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.


For full guidance
https://www.nice.org.uk/guidance/ng98

New NICE Diagnostics guidance [DG33] Biomarker tests to help diagnose preterm labour in women with intact membranes

New NICE Diagnostics guidance [DG33] Biomarker tests to help diagnose preterm labour in women with intact membranes


Published date: July 2018  Next review: July 2021


Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).


For full guidance
 https://www.nice.org.uk/guidance/dg33

New Quality standard [QS166] Trauma

New Quality standard [QS166] Trauma
Published date: March 2018  Next review: August 2018


This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.
For full guidance https://www.nice.org.uk/guidance/qs166

New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia

New Technology appraisal guidance [TA526] Arsenic trioxide for treating acute promyelocytic leukaemia
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta526

New Technology appraisal guidance [TA525] Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
For full guidance https://www.nice.org.uk/guidance/ta525

New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

New Technology appraisal guidance [TA524] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Published date: 13 June 2018  Next review: June 2021


Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
For full guidance https://www.nice.org.uk/guidance/ta524

New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia

New Technology appraisal guidance [TA523] Midostaurin for untreated acute myeloid leukaemia
Published date: 13 June 2018                 Next review: June 2021


Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
For full guidance https://www.nice.org.uk/guidance/ta523

New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

New Technology appraisal guidance [TA522] Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Published date: 13 June 2018                 Next review: More evidence on pembrolizumab is being collected, until November 2019. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then, as part of the managed access agreement


Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial carcinoma in adults.
for full guidance https://www.nice.org.uk/guidance/ta522

New Technology appraisal guidance [TA521] Guselkumab for treating moderate to severe plaque psoriasis

New Technology appraisal guidance [TA521] Guselkumab for treating moderate to severe plaque psoriasis
Published date: 13 June 2018                   Next review: June 2021
For full guidance https://www.nice.org.uk/guidance/ta521

New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

New Technology appraisal guidance [TA520] Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Published date: 16 May 2018  Next review: May 2021


Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
For full guidance https://www.nice.org.uk/guidance/ta520

New Interventional procedures guidance [IPG616] Intranasal phototherapy for allergic rhinitis

New Interventional procedures guidance [IPG616] Intranasal phototherapy for allergic rhinitis
Published date: June 2018  Next review: June 2021


Evidence-based recommendations on intranasal phototherapy for allergic rhinitis in adults. This involves using light to reduce inflammation inside the nose.
 For full guidance https://www.nice.org.uk/guidance/ipg616

New Interventional procedures guidance [IPG615] Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

New Interventional procedures guidance [IPG615] Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
Published date: May 2018  Next review: this guidance will be reviewed if there is new evidence or safety concerns.




Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
For full guidance https://www.nice.org.uk/guidance/ipg615

New Interventional procedures guidance [IPG614] Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer

New Interventional procedures guidance [IPG614] Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer
Published date: May 2018  Next review: May 2021


Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer in adults. This involves using heat energy both to clear blockage in the bile ducts before inserting stents and to clear blocked stents.


For full guidance https://www.nice.org.uk/guidance/ipg614

New NICE Interventional procedures guidance [IPG613] Percutaneous balloon valvuloplasty for fetal critical aortic stenosis

New NICE Interventional procedures guidance [IPG613] Percutaneous balloon valvuloplasty for fetal critical aortic stenosis
Published date: May 2018 Next review: May 2021


Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.


For full guidance https://www.nice.org.uk/guidance/ipg613

NICE - Antenatal and postnatal mental health: clinical management and service guidance

This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year.  Click here for further details. 

New NICE Technology appraisal guidance [TA519] Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

New NICE Technology appraisal guidance [TA519] Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy


Published date: 25 April 2018  


Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated locally advanced or metastatic urothelial carcinoma in adults.


For full guidance https://www.nice.org.uk/guidance/ta519

New NICE Interventional procedures guidance [IPG612] Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma

New NICE Interventional procedures guidance [IPG612] Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma


Published date: April 2018  Next review: April 2021


Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.


For full guidance https://www.nice.org.uk/guidance/ipg612